



Carbon Reduction Plan guidance

Notes for completion

Where an in-scope organisation has determined that the measure applies to the procurement, suppliers wishing to bid for that contract are required, as a condition of participation, to submit a CRP which details their organisational carbon footprint and confirms their commitment to achieving net zero by 2050.

CRPs are to be completed by the bidding supplier and must meet the reporting requirements set out in supporting guidance and include the supplier's current carbon footprint and its commitment to reducing emissions to achieve net zero emissions by 2050.¹

The CRP should be specific to the bidding entity, or, provided certain criteria are met, may cover the bidding entity and its parent organisation. In order to ensure the CRP remains relevant, a CRP covering the bidding entity and its parent organisation is only permissible where the detailed requirements of the CRP are met in full, as set out in the Technical Standard² and Guidance, and all of the following criteria are met:

- the bidding entity is wholly owned by the parent
- the commitment to achieving net zero by 2050 for UK operations is set out in the CRP for the parent and is supported and adopted by the bidding entity, demonstrated by the inclusion in the CRP of a statement that this will apply to the bidding entity
- the environmental measures set out are stated to be able to be applied by the bidding entity when performing the relevant contract
- the CRP is published on the bidding entity's website

Bidding entities must take steps to ensure they have their own CRP as soon as reasonably practicable and should note that the ability to rely on a parent organisation's CRP may only be a temporary measure to satisfy this particular condition of participation.

The CRP should be updated regularly (at least annually) and published and clearly signposted on the supplier's UK website. It should be approved by a director (or equivalent senior leadership) within the supplier's organisation to demonstrate a clear commitment to emissions reduction at the highest level. Suppliers may wish to adopt the objectives of the CRP within their strategic plans.

A template for the CRP is set out below. Please complete and publish your CRP in accordance with the reporting standard published alongside this PPN.

¹ 'Bidding supplier' or 'bidding entity' means, for the purpose of this guidance, the organisation with whom the Contracting Authority will enter into a contract if it is successful.

² <https://www.gov.uk/government/publications/ppn-006-guidance-on-taking-account-of-carbon-reduction-plans-adopting-and-applying-conditions-of-participation-html>

Carbon Reduction Plan

Supplier name: Renascience Pharma Limited

Publication date: 20 September 2026

Commitment to achieving net zero

Renascience Pharma Limited is committed to achieving net zero emissions by 2045.

Baseline emissions footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

Baseline year: 2024
Additional details relating to the baseline emissions calculations:

Renascience Pharma Limited has set its ambition to be Carbon Net Zero by 2045. The organisation has been assessed in Aug 2025 and is using calendar year 2024 as the baseline year. A GHG report has been prepared for the company assessment in accordance with Part 1 of ISO 14064: 2018 by Carbon Footprint Ltd.

Calendar year 2024 is the first year an organisational Green House Gas (GHG) assessment for Renascience Pharma Limited following its acquisition by Lupin Healthcare (UK) Limited in April 2025. During the reporting year Renascience Pharma Limited operated as a virtual company meaning it had no office and all staff were fully remote. Therefore Scope 3.5 waste generated in operations, Scope 3.7 Employee commuting and Scope 3.9 Downstream transportation and distribution are not applicable to Renascience and therefore not assessed. Owing to the recent acquisition and likely resulting changes to its operations it is recognised that the breadth and quality of the data available for this reporting year is limited and it may be necessary to rebase in subsequent reporting years.

Baseline year emissions:	
Emissions	Total (tCO2e) Location based
Scope 1	0.00
Scope 2 (Company vehicles (EV) charging)	0.85
Scope 3 (included sources)	3.1 Purchased Goods and Services (Spend): 47.17 Meals (Spend): 1.39 3.3 Scopes 1 and 2 WTT: 0.19 Company EV vehicles T&D: 0.05

	3.4 Upstream lorry freight: 11.79	
	3.6 International travel (Spend): 22.98 Hotels (Spend): 2.00 Taxi: 0.23 Rail: 0.16 Car transport (Spend): 0.13	
Total emissions		86.92

Current emissions reporting

Reporting year: 2024		
Emissions		Total (tCO2e) Location based
Scope 1		0.00
Scope 2 (Company vehicles (EV) charging)		0.85
Scope 3 (included sources)	3.1 Purchased Goods and Services (Spend): 47.17 Meals (Spend): 1.39 3.3 Scopes 1 and 2 WTT: 0.19 Company EV vehicles T&D: 0.05 3.4 Upstream lorry freight: 11.79 3.6 International travel (Spend): 22.98 Hotels (Spend): 2.00 Taxi: 0.23 Rail: 0.16 Car transport (Spend): 0.13	
Total emissions		86.92

For CY25 emission reporting and CRP planning will be amalgamated with our parent company 'Lupin Healthcare UK Ltd' (LHUK). CY25 emissions for LHUK are still being calculated and CRP updated. this will be published in Dec 2026. this CRP is therefore an interim plan, shortly to be superseded.

Emissions reduction targets

In order to reflect the expected growth of Renascience Pharma Limited sales and operations in the coming reporting years we have set carbon reduction targets based on per £M turnover. A clear roadmap for individual emissions sources will be put in place. This will ensure the strategy for reducing CO2e emissions and tracking toward a net zero target is appropriate for the business.

We project 50% reduction in emissions per £M turnover by 2030 with a targeted Net Zero emissions by 2045.

Carbon reduction projects

Completed carbon reduction initiatives

Renascience Pharma Limited was acquired by Lupin Healthcare (UK) limited in April 2025 and it is expected that there will be significant changes to its day-to-day operating practices and its suppliers. Furthermore, it is expected that there will be significant growth in both sales and operations all of which will have an impact on emissions. For these reasons it is expected a re-basing of emissions will be required in reporting year 2025. we have not been able to quantify all of the impact from historical initiatives, however the following emission initiatives have previously been implemented by Lupin Healthcare (UK) Limited from which Renascience Pharma Limited will benefit:

- Office waste recycle points have been in place since 2016
- PIR lighting controls within office space have been in place since 2016
- EV charging points available at the office site since 2021. Communication has been provided to promote the availability of this service to all employees.
- Implementing flexi-working in 2022 (post Covid-19), with office-based employees expected to be in the office 2 to 3 days a week
- Office electricity source moved to a fully renewable tariff in 2022
- Engagement with suppliers to provide emission reduction plans and targets.

Future carbon reduction initiatives

In the future we plan to implement further measures such as:

- Working closely with suppliers to further increase the transparency of the emissions from Renascience Pharma Limited purchased medicines. Increasing full transparency to raw material transportation, embodiment emissions and manufacture of Renascience Pharma Limited medicine spend, with clear action plans to reduce emissions for each
- Continuing to engage with the suppliers to align with long term (2045) net zero targets and action plans which align with the NHS ambitions.
- Engaging with suppliers to ensure shelf-life extension for new and key product lines and diary management increases sea freight to 75% of all shipments by 2030 (where safe to meet patient demand).
- Engaging with our logistics provider to ensure the transition between 2025-2040 for lower carbon fuel/ EV powered vehicles.
- Maintaining low carbon footprint for Renascience Pharma Limited UK operations, for example, via the encouragement of working from home where practical, low carbon opt out car incentives, economy flights if necessary, and contracting low carbon taxi services.

Declaration and sign off


This Carbon Reduction Plan has been completed in accordance with PPN 006 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard³ and uses the appropriate government emission conversion factors for greenhouse gas company reporting.⁴

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements (where required), and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard.⁵

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

Signed on behalf of the supplier:



Ben Ellis

General Manager

Date: 20/09/26

³ <https://ghgprotocol.org/corporate-standard>

⁴ www.gov.uk/government/collections/government-conversion-factors-for-company-reporting

⁵ <https://ghgprotocol.org/standards/scope-3-standard>